Compare Hims and Hers Health Inc (HIMS) vs Palantir Technologies Inc (PLTR) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

Palantir (PLTR) trades at $135.63, up 2.46% today, showing strong momentum despite being 35% below its 52-week high. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company demonstrates exceptional growth with 2025 revenue of $4.48 billion and net income of $1.63 billion, though valuation metrics remain elevated with a P/E of 148.74 and P/S of 65.12. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.33 surpassing the $0.2774 forecast.

Palantir's AI software leadership and accelerating revenue growth present compelling long-term potential, but the premium valuation creates significant risk if growth moderates. Analyst consensus leans bullish with a $185.75 price target, though the stock faces headwinds from competitive pressures and market rotation out of high-multiple software names. The company's strong government contracts and commercial expansion provide stability, but investors should weigh rich multiples against execution risks.